Daewoong Pharmaceutical Enblo Tablet
Daewoong Pharmaceutical announced on the 28th that a study has found its diabetes treatment “Enblo” (ingredient name: inavogliflozin) reduced blood leptin levels by about twice as much as dapagliflozin, another drug in the same SGLT-2 inhibitor class, and that the results were published in the international journal “Cardiovascular Diabetology.”
Leptin is an appetite-regulating hormone secreted by adipocytes. Some patients with type 2 diabetes accompanied by obesity exhibit “leptin resistance,” in which the body does not respond properly to leptin signals even when leptin is sufficiently secreted. Leptin resistance is also known to be associated with insulin resistance.
The findings are based on an integrated analysis of two existing phase 3 clinical trials of Enblo. The researchers administered Enblo and dapagliflozin, respectively, to 427 patients with type 2 diabetes for 24 weeks and compared changes in leptin levels, insulin resistance indices, and other parameters.
Analysis showed that after 24 weeks, the reduction in blood leptin was 2.08 μg/L in the Enblo group, about 1.9 times that of the dapagliflozin group (1.09 μg/L). A similar difference was observed even after statistically adjusting for the effects of weight change.
The insulin resistance index (HOMA-IR) also decreased by 1.36 in the Enblo group, indicating a greater improvement than in the dapagliflozin group, where it decreased by 1.05. In contrast, there was no significant difference between the two drugs in changes in glycated hemoglobin (HbA1c) and body weight.
The researchers explained that these results indicate that even among drugs in the same class of diabetes treatments, there may be differences in leptin and insulin metabolism-related indicators. However, further studies are needed to determine whether the reduction in leptin levels translates into long-term reductions in the risk of cardiovascular and renal disease.
Ryu Young-sang, professor in the Division of Endocrinology and Metabolism at Chosun University Hospital, said, “Enblo lowered leptin levels more than dapagliflozin, even after adjusting for weight change, and showed significant improvement in insulin resistance indices,” adding, “Further research is needed to elucidate the mechanisms underlying these changes.”
Park Hyeong-cheol, head of the ETC Marketing Division at Daewoong Pharmaceutical, stated, “Enblo showed a difference in the extent of leptin reduction in a direct comparison with a drug in the same class,” and added, “We will continue to build evidence related to cardiovascular, renal, and metabolic health.”
Enblo is a type 2 diabetes treatment developed by Daewoong Pharmaceutical and belonging to the SGLT-2 inhibitor class. It lowers blood glucose by inhibiting glucose reabsorption in the kidneys and promoting the excretion of glucose in the urine.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
Popular News